Michael W Schuster MD

Oncology•New York, NY

Hematologic Oncology

Professor of Hematology & Oncology, SUNY Stony Brook

Join to View Full Profile

520 E 70th St# StarrNew York, NY 10021
Phone+1 212-746-2119
Fax+1 212-746-3305

Summary

Dr. Michael Schuster is an oncologist based in New York, NY, specializing in hematologic oncology. He completed his medical education at the Geisel School of Medicine at Dartmouth, followed by a residency and fellowship at Beth Israel Deaconess Medical Center. His clinical expertise includes bone marrow transplantation, Hodgkin's lymphoma, multiple myeloma, and graft-versus-host disease. Dr. Schuster has contributed to numerous publications in notable journals such as the Journal of Clinical Oncology and Blood Advances. He has held the role of Principal Investigator in multiple clinical trials focused on hematologic cancers. Over his career, he has been recognized several times by Castle Connolly and New York Magazine as a top doctor in oncology.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1987
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1980 - 1983
Geisel School of Medicine at DartmouthClass of 1980

Certifications & Licensure

CA State Medical License 1981 - Present
MA State Medical License 1982 - 2027
NY State Medical License 1987 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Newsday - Top Doctors on Long Island Castle Connolly, 2011-2020
America's Top Doctors for Cancer Castle Connolly, 2005-2020
Top Doctors: New York Metro Area Castle Connolly, 2003-2014, 2016-2020

Clinical Trials

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients Start of enrollment: 2010 Jun 01
Terminated
Phase 2
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3

Publications & Presentations

PubMed

Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients u...
Devki D Sukhtankar, Pina M Cardarelli, Bita Jalilizeinali, Gayatri Setia, GaYeon Kim
Annals of Hematology. 2026-02-04
A Relapsed AML Case Featuring MYC and MECOM Rearrangements.
Kevin A Murgas, Pons Materum 3rd, Luke Z Li, Jacob Rocha, Michael Schuster
Diagnostics. 2025-09-22
10 citations
Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2025-01-10

Abstracts/Posters

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...
Michael W. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid LeukemiaClinically Relevant Abstract
Michael W. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantFebruary 11th, 2026

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member